AQST 8-K: SEC filing

Filed with the SEC on Nov 5, 2026 · accession 0001398733-26-000077

AQST filed a 8-K (current report) with the SEC on Nov 5, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Aquestive Therapeutics furnished an investor presentation to be used in meetings with institutional investors and analysts, disclosed under Regulation FD via an 8-K filing.

For details, click here →How to read a 8-K →

Key details

RegistrantAquestive Therapeutics, Inc.

Chief financial officerA. Ernest Toth, Jr.

✦ Ask GOAX AI about this filing — what it means for AQST, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for AQST?

Click here

Frequently asked questions

What did AQST file with the SEC on Nov 5, 2026?

AQST filed a 8-K (SEC filing). Aquestive Therapeutics furnished an investor presentation to be used in meetings with institutional investors and analysts, disclosed under Regulation FD via an 8-K filing.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other AQST SEC filings

Get alerts when AQST files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

AQST overview AQST analysis AQST news Latest SEC filings